Jul 15, 2026 07:31AM
Jul 15, 2026 07:30AM
Jul 7, 2026 07:30AM
Jun 17, 2026 12:30PM
Jun 16, 2026 07:32AM
Jun 16, 2026 07:30AM
May 12, 2026 07:00AM Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Mar 26, 2026 07:00AM
Mar 17, 2026 08:00AM
Mar 17, 2026 08:00AM
Mar 3, 2026 08:00AM
Mar 3, 2026 08:00AM
Jan 27, 2026 05:59AM
Dec 2, 2025 08:00AM Acumen Pharmaceuticals presents brain delivery technology at CTAD conference
Dec 2, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 17, 2025 08:00AM
Nov 17, 2025 08:00AM
Nov 12, 2025 07:00AM
Aug 12, 2025 07:00AM Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
Jul 28, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 15, 2025 07:01AM
Jul 15, 2025 07:00AM
Jul 10, 2025 08:00AM
May 13, 2025 07:00AM
Apr 2, 2025 07:00AM Acumen Pharmaceuticals, Inc (ABOS) Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Apr 2, 2025 07:00AM
Apr 1, 2025 07:00AM
Mar 27, 2025 07:00AM
Mar 26, 2025 08:05AM
Mar 26, 2025 08:00AM
Mar 19, 2025 08:00AM
Mar 19, 2025 08:00AM Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
Mar 12, 2025 08:00AM
Jan 9, 2025 08:00AM
Nov 12, 2024 07:00AM
Nov 6, 2024 08:01AM
Nov 6, 2024 08:00AM
Nov 6, 2024 08:00AM
Oct 31, 2024 08:05AM Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alz
Oct 23, 2024 08:02AM
Oct 23, 2024 08:00AM
Sep 26, 2024 08:02AM
Sep 26, 2024 08:00AM
Aug 13, 2024 07:00AM
Jul 29, 2024 07:00AM
Jul 28, 2024 07:30AM Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Jul 11, 2024 08:00AM

326,550 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All